Navigator II Continuous Glucose Monitor Home Use Study
FreeStyle Navigator II Continuous Glucose Monitor Home Use Evaluation (FSNv2)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Atlanta Diabetes Associates
-
-
New Mexico
-
Santa Fe, New Mexico, United States, 87505
- Southwest Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
The subject must:
- Have type 1 or 2 diabetes for at least 2 years prior to enrollment.
- Require insulin therapy administered through an insulin pump or multiple daily injections (MDI) for at least 6 months prior to enrollment.
- Be at least 18 years of age.
- Be able to read and understand English.
- In the investigator's opinion, be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.
- Be available for all study visits.
- Be willing to provide written signed and dated informed consent.
Exclusion Criteria:
The subject must not:
- Be pregnant or likely to become pregnant during the study duration.
- Have skin abnormalities at the insertion sites.
- Have known allergy to medical grade adhesive or skin disinfectant.
- Be using a continuous glucose monitor currently or within the past 6 months
- Have a concomitant medical condition which, in the opinion of the investigator, could interfere with the study or present a risk to the safety or welfare of the subject.
- Be participating in another clinical trial.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Type 1 or 2 diabetes, MDI or pump
|
This is not an interventional study.
Subjects must maintain their own diabetes treatment regimen throughout the study duration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clarke Error Grid Analysis
Time Frame: 15 days sensor wear
|
Percentage of CGM results in the clinically accurate Zone A and percentage of CGM results in the clinically acceptable Zones A and B of the Clarke Error Grid versus blood glucose reference.
|
15 days sensor wear
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Shridhara A Karinka, Ph.D., Abbott Diabetes Care
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- ADC11-106
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.